泰它西普在自身免疫性疾病中的应用最新进展
The Latest Progress in the Application of Telitacicept in Autoimmune Diseases.
作者信息
Liu Baocheng, Zhao Yaqi, Liu Dongxia, Li Xinya, Ma Zhenzhen, Yang Qingrui
机构信息
Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, People's Republic of China.
Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, People's Republic of China.
出版信息
Drug Des Devel Ther. 2024 Dec 7;18:5811-5825. doi: 10.2147/DDDT.S493923. eCollection 2024.
INTRODUCTION
Humoral immunity plays a key role in the pathogenesis of autoimmune diseases, and B-lymphocyte activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are essential for the maintenance of B-lymphocyte reservoirs and humoral immunity. In March 2021, telitacicept, the world's first dual target three-channel biologic, was approved in China for the treatment of SLE and is currently in clinical trials exploring multiple indications for other autoimmune diseases.
AREAS COVERED
This article summarizes the mechanism of action, pharmacokinetics, and clinical efficacy of telitacicept for the treatment of multiple autoimmune diseases.
EXPERT OPINION
So far, the efficacy and safety of telitacicept in autoimmune diseases have been fully demonstrated in clinical practice. There are still many unresolved issues regarding the timing of initiation and discontinuation, still needs to be evaluated in future studies.
引言
体液免疫在自身免疫性疾病的发病机制中起关键作用，B淋巴细胞激活因子（BAFF）和增殖诱导配体（APRIL）对于维持B淋巴细胞库和体液免疫至关重要。2021年3月，全球首个双靶点三通道生物制剂泰它西普在中国获批用于治疗系统性红斑狼疮（SLE），目前正处于临床试验阶段，探索用于其他自身免疫性疾病的多种适应症。
涵盖领域
本文总结了泰它西普治疗多种自身免疫性疾病的作用机制、药代动力学及临床疗效。
专家观点
到目前为止，泰它西普在自身免疫性疾病中的疗效和安全性已在临床实践中得到充分证明。关于开始和停止用药的时机仍有许多未解决的问题，仍需在未来研究中进行评估。
Zotero 插件